CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced two presentations at the 59th Annual Meeting for the American College of Neuropsychopharmacology (ACNP). The conference was held virtually from December 6th to 9th, 2020.
The presentations included two posters, both of which discussed the potential utility of TRV045 to treat a variety of CNS disorders, including epilepsy, chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy (DPN). The Company is currently collaborating with the National Institutes of Health (NIH) to evaluate TRV045 in their screening programs for epilepsy and non-addictive treatment of pain.
“These are compelling nonclinical findings for TRV045 and support its potential application in the treatment of epilepsy and neuropathic pain. We look forward to continuing to investigate the potential of TRV045 as a treatment for these debilitating disorders,” said Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena, Inc.
- “TRV045, a novel, selective S1PR1 modulator, is efficacious in reversing neuropathic pain without affecting lymphocyte trafficking” (Poster #T125)
- TRV045 demonstrated efficacy comparable to fingolimod, an approved S1P receptor modulator, in a mouse CIPN model. Unlike fingolimod, TRV045 did not cause lymphopenia at therapeutic doses.
- TRV045 demonstrated efficacy comparable to gabapentin, an approved anticonvulsant medication sometimes used to treat diabetic neuropathy, in a rat diabetic peripheral neuropathy model. The Company believes this is the first time that modulation of the S1P1 receptor has been shown to have potential therapeutic benefit in reversing diabetic neuropathic pain.
- “TRV045, a novel, selective S1P1 receptor modulator that is not an immunosuppressant, is efficacious in rodent models of epilepsy” (Poster #W105)
- TRV045 was evaluated as a potential anti-epileptic treatment in four well-established rodent seizure models, as part of the NIH’s Epilepsy Therapy Screening Program (ETSP).
- TRV045 demonstrated a dose-dependent seizure prevention response in three of the models.
- TRV045 does not cause lymphopenia at therapeutic doses, suggesting it may offer unique therapeutic benefits in a variety of CNS indications, including epilepsy, where immunosuppression is not desirable. Notably, fingolimod has also shown efficacy in rodent epilepsy models, but with substantial immunosuppression.
All posters can be found at https://www.trevena.com/publications.
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.